BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palechor-Ceron N, Krawczyk E, Dakic A, Simic V, Yuan H, Blancato J, Wang W, Hubbard F, Zheng YL, Dan H, Strome S, Cullen K, Davidson B, Deeken JF, Choudhury S, Ahn PH, Agarwal S, Zhou X, Schlegel R, Furth PA, Pan CX, Liu X. Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks. Cells 2019;8:E1327. [PMID: 31717887 DOI: 10.3390/cells8111327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang C, Yang C, Yarden Y, To KKW, Fu L. The prospects of tumor chemosensitivity testing at the single-cell level. Drug Resist Updat 2021;54:100741. [PMID: 33387814 DOI: 10.1016/j.drup.2020.100741] [Reference Citation Analysis]
2 Zhu S, Zhu Z, Ma AH, Sonpavde GP, Cheng F, Pan CX. Preclinical Models for Bladder Cancer Research. Hematol Oncol Clin North Am 2021;35:613-32. [PMID: 33958154 DOI: 10.1016/j.hoc.2021.02.007] [Reference Citation Analysis]
3 Li Y, Guo D, Zhang Y, Wang L, Sun T, Li Z, Zhang X, Wang S, Chen Y, Wu A. Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay. Transl Oncol 2021;14:100935. [PMID: 33190042 DOI: 10.1016/j.tranon.2020.100935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ramzy GM, Koessler T, Ducrey E, McKee T, Ris F, Buchs N, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P. Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers (Basel) 2020;12:E1423. [PMID: 32486365 DOI: 10.3390/cancers12061423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
5 Liu X, Mondal AM. Conditional cell reprogramming for modeling host-virus interactions and human viral diseases. J Med Virol 2020;92:2440-52. [PMID: 32478897 DOI: 10.1002/jmv.26093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Varrone F, Mandrich L, Caputo E. Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going? Cancers (Basel) 2021;13:5788. [PMID: 34830940 DOI: 10.3390/cancers13225788] [Reference Citation Analysis]
7 Xia S, Wu M, Chen S, Zhang T, Ye L, Liu J, Li H. Long Term Culture of Human Kidney Proximal Tubule Epithelial Cells Maintains Lineage Functions and Serves as an Ex vivo Model for Coronavirus Associated Kidney Injury. Virol Sin 2020;35:311-20. [PMID: 32602046 DOI: 10.1007/s12250-020-00253-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
8 Meisel CT, Pagella P, Porcheri C, Mitsiadis TA. Three-Dimensional Imaging and Gene Expression Analysis Upon Enzymatic Isolation of the Tongue Epithelium. Front Physiol 2020;11:825. [PMID: 32848819 DOI: 10.3389/fphys.2020.00825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ci X, Hao J, Dong X, Xue H, Wu R, Choi SYC, Haegert AM, Collins CC, Liu X, Lin D, Wang Y. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. Cells 2020;9:E1398. [PMID: 32512818 DOI: 10.3390/cells9061398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Dong Y, Wang J, Ji W, Zheng M, Wang P, Liu L, Li S. Preclinical Application of Conditional Reprogramming Culture System for Laryngeal and Hypopharyngeal Carcinoma. Front Cell Dev Biol 2021;9:744969. [PMID: 34778255 DOI: 10.3389/fcell.2021.744969] [Reference Citation Analysis]
11 Wu M, Hong G, Chen Y, Ye L, Zhang K, Cai K, Yang H, Long X, Gao W, Li H. Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural effusion. J Int Med Res 2020;48:300060520955058. [PMID: 32954884 DOI: 10.1177/0300060520955058] [Reference Citation Analysis]
12 Zhao R, Li R, An T, Liu X. Conditional Cell Reprogramming in Modeling Digestive System Diseases. Front Cell Dev Biol 2021;9:669756. [PMID: 34150763 DOI: 10.3389/fcell.2021.669756] [Reference Citation Analysis]
13 Lee HS, Kim E, Lee J, Park SJ, Hwang HK, Park CH, Jo SY, Kang CM, Hong SM, Kang H, Jo JH, Cho IR, Chung MJ, Park JY, Park SW, Song SY, Han JM, Kim S, Bang S. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine 2021;65:103218. [PMID: 33639403 DOI: 10.1016/j.ebiom.2021.103218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sui JSY, Martin P, Gray SG. Pre-clinical models of small cell lung cancer and the validation of therapeutic targets. Expert Opin Ther Targets 2020;24:187-204. [PMID: 32068452 DOI: 10.1080/14728222.2020.1732353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Takahashi N, Higa A, Hiyama G, Tamura H, Hoshi H, Dobashi Y, Katahira K, Ishihara H, Takagi K, Goda K, Okabe N, Muto S, Suzuki H, Shimomura K, Watanabe S, Takagi M. Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncol Lett 2021;21:406. [PMID: 33841567 DOI: 10.3892/ol.2021.12667] [Reference Citation Analysis]
16 Liu W, Ju L, Cheng S, Wang G, Qian K, Liu X, Xiao Y, Wang X. Conditional reprogramming: Modeling urological cancer and translation to clinics. Clin Transl Med 2020;10:e95. [PMID: 32508060 DOI: 10.1002/ctm2.95] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther 2021;6:423. [PMID: 34924565 DOI: 10.1038/s41392-021-00826-7] [Reference Citation Analysis]
18 Zhong M, Fu L. Culture and application of conditionally reprogrammed primary tumor cells. Gastroenterol Rep (Oxf) 2020;8:224-33. [PMID: 32665854 DOI: 10.1093/gastro/goaa023] [Reference Citation Analysis]
19 Trusler O, Goodwin J, Laslett AL. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochim Biophys Acta Rev Cancer 2021;1875:188459. [PMID: 33129865 DOI: 10.1016/j.bbcan.2020.188459] [Reference Citation Analysis]
20 Shi J, Wei L. Rho Kinases in Embryonic Development and Stem Cell Research. Arch Immunol Ther Exp 2022;70. [DOI: 10.1007/s00005-022-00642-z] [Reference Citation Analysis]
21 Joshi R, Castro De Moura M, Piñeyro D, Alvarez-Errico D, Arribas C, Esteller M. The DNA methylation landscape of human cancer organoids available at the American type culture collection. Epigenetics 2020;15:1167-77. [PMID: 32396494 DOI: 10.1080/15592294.2020.1762398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Shelton SE, Nguyen HT, Barbie DA, Kamm RD. Engineering approaches for studying immune-tumor cell interactions and immunotherapy. iScience 2021;24:101985. [PMID: 33490895 DOI: 10.1016/j.isci.2020.101985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Zhou L, Zhang C, Zhang Y, Shi C. Application of Organoid Models in Prostate Cancer Research. Front Oncol 2021;11:736431. [PMID: 34646778 DOI: 10.3389/fonc.2021.736431] [Reference Citation Analysis]
24 Liu X, Wu Y, Rong L. Conditionally Reprogrammed Human Normal Airway Epithelial Cells at ALI: A Physiological Model for Emerging Viruses. Virol Sin 2020;35:280-9. [PMID: 32557270 DOI: 10.1007/s12250-020-00244-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhao W, Liu K, Sun Z, Wang L, Liu B, Liu L, Qu X, Cao Z, Sun J, Chai J. Application Research of Individualized Conditional Reprogramming System to Guide Treatment of Gastric Cancer. Front Oncol 2021;11:709511. [PMID: 34336697 DOI: 10.3389/fonc.2021.709511] [Reference Citation Analysis]